IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company...
Australia and New Zealand's Skin Cancer Governance Gap Exposed: 40% of Organisations Never Assessed Workforce Risk Despite 84% Believing Duty of Care Applies
New research reveals a critical blind spot in workplace health and safety compliance - even as boards demand better programs SYDNEY, Feb. 10, 2026 /PRNewswire/ -- A comprehensive new report on workplace skin cancer screening in Australia and New...
